Statin Therapy Cost-Effectively Improves Health Outcomes for ≥70s
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 12, 2024 -- Statin therapy improves health outcomes and is cost-effective for men and women aged 70 years and older, according to a study published online Sept. 10 in Heart.
Borislava Mihaylova, D.Phil., from the University of Oxford in the United Kingdom, and colleagues examined the long-term effects and cost-effectiveness of statin therapy for older adults in a meta-analysis and a new validated cardiovascular disease (CVD) model. Performance of the CVD microsimulation model was examined among participants aged 70 years and older at (re)surveys in the U.K. Biobank and Whitehall II studies. Participants' cardiovascular risks, survival, quality-adjusted life years (QALYs), and health care costs were projected with and without lifetime standard (35 to 45 percent low-density lipoprotein cholesterol reduction) or higher-intensity (≥45 percent reduction) statin therapy.
The researchers found that lifetime use of a standard statin increased QALYs by 0.24 to 0.70 per person and use of a higher-intensity statin increased QALYs by a further 0.04 to 0.13 per person in categories of men and women 70 years and older without and with prior CVD (15,019 and 5,103 participants, respectively). Statin therapies were cost-effective, with an incremental cost per QALY gained below £3,502 and below £11,778/QALY for standard and higher-intensity statin therapy, respectively, and with high probability of being cost-effective. Statins remained cost-effective in sensitivity analyses, although there was more uncertainty for older people without previous CVD.
"While further randomized evidence will be helpful, the robustness of these findings indicates that older people are likely to benefit cost-effectively from statin therapy and should be considered for treatment," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C
FRIDAY, March 28, 2025 -- Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin...
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
FRIDAY, Feb. 21, 2025 -- Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.